DPP10: Potential Drug Target and Biomarker for Neurological Disorders

Target Name: DPP10

NCBI ID: G57628

DPP10: Potential Drug Target and Biomarker for Neurological Disorders

DPP10, also known as DPP10 variant 2, is a protein that is expressed in the brain and has been linked to a number of neurological and psychiatric disorders. The most well-known of these disorders is Alzheimer's disease, which is a degenerative brain disorder that is characterized by the progressive loss of brain cells and the development of aggregates of the protein beta-amyloid.

DPP10 is a transmembrane protein that is expressed in the brain and is involved in the regulation of various signaling pathways that are involved in the development and progression of neurological and psychiatric disorders. It is made up of four structural domains: an N-terminus, a T-terminus, a middle domain, and an C-terminus.

The N-terminus of DPP10 is a 21-amino acid residue that is involved in the interaction with other proteins. The T-terminus of DPP10 is a 24-amino acid residue that is involved in the interaction with the protein p100, which is a neurotransmitter that is involved in the regulation of anxiety and depression. The middle domain of DPP10 is the largest of the four domains and is involved in the regulation of various signaling pathways that are involved in the development and progression of neurological and psychiatric disorders.

DPP10 has been linked to a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. It is thought to play a role in the regulation of the neurotransmitter circuitry that is involved in the development and progression of these disorders.

One of the most promising aspects of DPP10 is its potential as a drug target. Because DPP10 is involved in the regulation of various signaling pathways that are involved in the development and progression of neurological and psychiatric disorders, it is a potential target for the development of new treatments for these disorders.

In addition to its potential as a drug target, DPP10 is also a potential biomarker for the diagnosis and progression of neurological and psychiatric disorders. Because it is expressed in the brain and is involved in the regulation of various signaling pathways that are involved in the development and progression of these disorders, it is a potential indicator of the presence of these disorders.

DPP10 is also thought to be involved in the regulation of the immune system, which is a critical part of the body's defense against infection and disease. This suggests that DPP10 may have implications for the development of new treatments for a wide range of disorders, including neurological and psychiatric disorders.

In conclusion, DPP10 is a protein that is expressed in the brain and has been linked to a number of neurological and psychiatric disorders. The most well-known of these disorders is Alzheimer's disease, but DPP10 is also thought to be involved in the regulation of various signaling pathways that are involved in the development and progression of these disorders. As a result, DPP10 is a potential drug target and a potential biomarker for the diagnosis and progression of these disorders. Further research is needed to fully understand the role of DPP10 in the regulation of the brain and the development and progression of neurological and psychiatric disorders.

Protein Name: Dipeptidyl Peptidase Like 10

Functions: Promotes cell surface expression of the potassium channel KCND2 (PubMed:15454437). Modulates the activity and gating characteristics of the potassium channel KCND2 (PubMed:15454437). Has no dipeptidyl aminopeptidase activity (PubMed:12662155)

More Common Targets